LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.